Global Health Ventures Starts Manufacturing of X-Excite Under GMP Contract in Europe

VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 14, 2009) - Global Health Ventures Inc. (OTCBB: GHLV) (the “Company”) is pleased to announce that it has signed an agreement with Pharmex Rom Industries SRL of Bucharest to manufacture X-Excite drug under GMP protocol. Pharmex is a contract manufacturer of pharmaceutical drugs for human use. Pharmex is a certified GMP (Good Manufacturing Practice) under the European Regulatory Guidance (EMEA) and Japanese Regulatory guidance. Under the terms of the agreement Pharmex shall manufacture X-Excite for clinical trials in Europe and other countries that recognize European Regulatory Authority’s approval.

“We have chosen a strategy to first develop our drugs in Europe, as a large number of countries recognize European Regulatory Approval and the cost of development to the Company is lower than FDA Approval. We have however planned to carry out the trials under the FDA guidance after the European approval,” said Dr. Hassan Salari, Global Health President and CEO.

X-Excite is a male sexual enhancement drug. It is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. It is expected that the market for such products may continue to grow and the Company hopes to capture a sizable portion of this market.

About Global Health Ventures

The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company has also a novel dermal delivery system for delivery of products intended to work locally.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Even if the Company is able to raise funds to develop products, still the chance of failure for drug approval is very high. Investors are encouraged to review the risk factors listed or described from time to time in the Company’s filings (10K) with the Securities and Exchange Commission.